More than 100 million people in Europe and beyond trust our products.

Zentiva operates four wholly owned manufacturing sites in Prague, Bucharest, and Ankleshwar, supported by a broad network of external manufacturing partners to ensure supply security. We produce a diverse range of pharmaceuticals, including solids, injectable solutions, eye drops, sterile ointments, hormones, APIs, and intermediates, with a total production volume of 588 million SMUs in 2024. Our sites actively implement a comprehensive sustainability program focused on efficiency improvements and on decarbonization, with all European sites powered by 100% renewable electricity.

Together with our partners, we adhere to our Suppliers Code of Conduct and regularly assess third-party collaborations through our Responsible Sourcing Program. Upstream, we focus on direct suppliers while progressively expanding our scope to meet the requirements of the upcoming Corporate Sustainability Due Diligence Directive (CSDDD). Downstream, we prioritize the wellbeing of end consumers and patients who rely on our medicines daily. We uphold the highest product quality standards and ensure patient safety through a robust pharmacovigilance system.

While our network is global, we remain committed to minimizing environmental impact wherever possible.